Preliminary results from clinical trial of digital vs. film mammography showed no difference in breast cancer detection
On Sept. 16, 2005, preliminary results from a large, clinical trial of digital vs. film mammography showed no…
-
-
David H Murdock announced a $1.5 billion North Carolina Research Campus
On Sept. 12, 2005, David H. Murdock announced a $1.5 billion scientific and economic revitalization project called the…
-
A vaccine that combined the measles, mumps, rubella, and varicella antigens was licensed
On Sept. 6, 2005, the vaccine that combined the measles, mumps, rubella, and varicella antigens (Proquad by Merck)…
-
An inactivated, injectable influenza vaccine was licensed
On Aug. 31, 2005, the inactivated, injectable influenza vaccine (Fluarix) by GlaxoSmithKline (GSK) was licensed. The vaccine was…
-
The CDC responded to the crises presented by Hurricanes Katrina and Rita
On Aug. 29, 2005, the U.S. Centers for Disease Control and Prevention (CDC) responded to the crises presented…
-
FDA approved lowering the age limit to 12 mos for one of the two licensed hepatitis A vaccine
On Aug. 11, 2005, the Food and Drug Administration (FDA) approved an application of a pediatric/adolescent formulation of…
-
The Energy Policy Act was signed into law, authorizing incentives for bioethanol development
On Aug. 8, 2005, the Energy Policy Act ( P.L. 109-58 ) was passed by the U.S. Congress…
-
Life Sciences Discovery Fund Authority was created to help finance groundbreaking R&D
On Jul. 13, 2005, The Life Sciences Discovery Fund Authority (LSDF) was established and a total of $350…
-
Corixa Corp. was acquired by Glaxosmithkline for $300 million
On Jul. 12, 2005, Corixa Corp., based on First Hill in Seattle, was acquired by Glaxosmithkline (GSK) for…
-
Biotechnology | Disease | NIH | Oncology | Therapeutics
The Patient Navigator Outreach and Chronic Disease Prevention Act amended the Public Health Service Act
On Jun. 29, 2005, the Patient Navigator Outreach and Chronic Disease Prevention Act of 2005 (P.L. 109-18) amended…
-
FDA licensed a 2nd Tdap vaccine (Adacel by Sanofi Pasteur) for use in persons ages 11-64 years
On Jun. 9, 2005, the U.S. Food and Drug Administration (FDA) announced it had expanded the approved age…
-
Andras Nagy announced Canada’s first human embryonic stem cell lines
On Jun 8, 2005, Dr. Andras Nagy at Mount Sinai Hospital announced Canada’s first human embryonic stem cell…
-
OMRF’s Sir Alexander Fleming scholar program celebrated it’s 50th class
On Jun. 8, 2005, the Oklahoma Medical Research Foundation’s Sir Alexander Fleming scholar program celebrated it’s 50th class…
-
The National Cancer Institute announced the Community Networks Program
On May 6, 2005, the National Cancer Institute announced the Community Networks Program (CNP), a 5-year initiative to…
-
Cellular pertussis vaccine combined with adult formulation of tetanus and diphtheria licensed in persons 10-18 years of age
On May 3, 2005, the cellular pertussis vaccine combined with the adult formulation of tetanus and diphtheria (Tdap:…
-
Karmanos Cancer Institute acquired clinical facilities from the Detroit Medical Center
On May 1, 2005, the Wayne State University Karmanos Cancer Institute announced it had acquired its clinical facilities…
-
NCI-sponsored clinical trials showed patients with early-stage, HER2-positive, invasive breast cancer experienced decrease in risk of cancer recurrence
On Apr. 27, 2005, results from two large National Cancer Institute sponsored randomized clinical trials showed that patients…
-
Biotechnology | Diagnostics | Disease | NIH | Oncology | Women's Health
NCI trial reported targeted agent trastuzumab and standard chemo cut risk of HER-2-positive breast cancer
On Apr. 25, 2005, the combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk…
-
Biotechnology | Genomics | NIH | Oncology | Therapeutics
The National Cancer Institute announced the creation of the cancer Biomedical Informatics Grid
On Apr. 12, 2005, the National Cancer Institute (NCI) announced the creation of the cancer Biomedical Informatics Grid…
-
Moores Cancer Center at UC San Diego opened new consolidated facility
On Apr. 8, 2005, Moores Cancer Center (MCC) at University of California, San Diego opened its new consolidated…
-
HHS awarded a contract for $97 million to Sanofi Pasteur to develop cell culture-based influenza vaccines for the U.S.
On Apr. 1, 2005, Sanofi pasteur was awarded a five-year $97 million contract from the U.S. Department of…
-
CDC announced that rubella was no longer endemic in the U.S.
On Mar. 21, 2005, the U.S. Centers for Disease Control and Prevention (CDC) announced that a major public…
-
Biotechnology | HIV | Infectious Disease | Neurology | Non-Profit Research | Oncology | Stem Cell | Therapeutics
UCLA launched $20 million stem cell institute to investigate new approaches to HIV, cancer and neurological disorders
On Mar. 16, 2005, University of California, Los Angeles (UCLA) officials announced the formation of the Institute for…
-
First cloned horse was born in North America
On Mar. 13, 2005, Paris Texas, the first cloned horse in North America was born at the College…
-
The Nebraska Biocontainment Unit was established at UNMC
On Mar. 7, 2005, the Centers for Disease Control and Prevention (CDC) commissioned the Nebraska Biocontainment Unit (NBU) at…
-
The FDA’s Drug Safety Oversight Board was formed
On Feb. 15, 2005, in response to concerns about the safety of a number of prescription medicines, the…
-
Autism Speaks was founded in New York City
On Feb. 11, 2005, Autism Speaks was founded in New York City by Bob and Suzanne Wright, grandparents…
-
The first meningococcal polysaccharide diphtheria toxoid conjugate vaccine (Menactra by Sanofi Pasteur) was licensed
On Jan. 14, 2005, the first meningococcal polysaccharide (Serogroups A, C, Y and W-135) diphtheria toxoid conjugate vaccine…
-
The Institute for Translational Medicine and Therapeutics (ITMAT) was established
In Jan. 2005, the Institute for Translational Medicine and Therapeutics (ITMAT) was established at Penn’s Perelman School of…
-
Biotechnology | Diagnostics | Disease | FDA | Nanotechnology | Oncology | Therapeutics
FDA approved albumin-stabilized nanoparticle formulation of paclitaxel for treatment of breast cancer
In Jan. 2005, the U.S. Food and Drug Administration (FDA) approved an albumin-stabilized nanoparticle formulation of paclitaxel (Abraxane)…
